Drug intelligence / Profile preview

2-(cyclohexylamino)benzoic acid

Development stage: Unknown
Modality: Small Molecules

Overview

2-(cyclohexylamino)benzoic acid is a benzoic acid derivative featuring a cyclohexylamino group attached to the benzene ring. It is classified as a small molecule and has been investigated primarily as an experimental compound. Its main mechanism of action is inhibition of serine/threonine-protein kinase Chk1, which plays a key role in cell cycle regulation and DNA damage response pathways. The compound has not been approved for any therapeutic use and remains at the discovery or investigative stage, with no clinical trials reported beyond preclinical research[1][5][3].

Other names: 2-Cyclohexylamino-benzoic acidBenzoic acid, 2-(cyclohexylamino)-Acide 2-(cyclohexylamino)benzoïque10286-53-0

Targets

CHEK1 (Checkpoint kinase 1)

Beyond the preview

Go deeper on 2-(cyclohexylamino)benzoic acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 2-(cyclohexylamino)benzoic acid.

Explore the full profile